#United States #Athens #Cancer Care #Theranostics #University Cancer Center

University Cancer & Blood Center Achieves National Recognition

The University Cancer & Blood Center (UCBC), a prominent oncology and hematology institution based in Northeast Georgia, has been awarded the prestigious designation of Clinical Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). This honor not only underscores UCBC's commitment to excellence in cancer treatment but also positions it among a select group of 37 centers nationwide recognized for their capabilities in delivering radiopharmaceutical therapies.

Radiopharmaceutical therapies, commonly referred to as theranostics, are advanced treatments that utilize targeted radioactive compounds. These potent therapies are designed to precisely identify and treat diseases at the cellular level, allowing for the direct delivery of radiation to cancerous cells. By targeting cancer cells specifically, theranostics aim to minimize damage to surrounding healthy tissues, effectively treating various conditions including thyroid and prostate cancers, neuroendocrine tumors, certain lymphomas, blood cancers, and bone metastases.

A Trailblazer in Community-Based Cancer Care

UCBC proudly stands as the first community-based cancer center in Georgia to offer theranostics outside of a hospital setting and among the few in the nation that have achieved SNMMI’s authorization. This signifies not only UCBC's excellence in patient care but also its dedication to making cutting-edge cancer treatments accessible to the community.

Jamie M. Maurer, the CEO of UCBC, expressed pride in the center's accomplishments, stating, “Being named a Clinical Center of Excellence is something we're truly proud of and places our practice among the very best in the country. We've got a special team here, and this recognition reflects the care, effort, and teamwork that goes into taking care of our patients every single day.”

Unwavering Commitment to Quality Care

Achieving the SNMMI designation required UCBC to meet stringent clinical, regulatory, and quality standards, ensuring that the organization has the necessary training, personnel, equipment, and clinical experience to effectively implement radiopharmaceutical therapies. The criteria necessitate a proven multidisciplinary theranostics program, strict adherence to safety and quality standards, and a steadfast commitment to ongoing education and research.

The leadership of Dr. Chris Tuttle and Dr. Gordon O. Schoenfeld, a board-certified radiation oncologist, has been instrumental in establishing the robust theranostics program at UCBC. Both have cultivated a team of highly skilled professionals who have trained or worked at some of the nation’s leading cancer centers, thereby ensuring that patients receive the most advanced therapeutic options available.

A Legacy of Leadership in Cancer Treatment

For over 40 years, UCBC has remained at the forefront of cancer and hematology treatment in Northeast Georgia. The center not only excels in clinical care but also boasts a comprehensive clinical research program, promoting innovative therapies and personalized treatment plans tailored to individual patient needs.

With this latest recognition, UCBC strengthens its commitment to providing innovative, high-quality cancer care while expanding access to cutting-edge therapies within the community it serves.

In summary, the designation of UCBC as a Center of Excellence by SNMMI stands as a testament to its dedication to patient care and positions it as a leader in the field of oncology, capable of offering state-of-the-art treatment options to improve patient outcomes across Northeast Georgia.